Scholarlink

<p>Osteomyelitis is a bone infection marked by inflammation and swelling, with persistent challenges in diagnosis and treatment, especially in chronic and therapy-resistant pediatric cases. Within the scope of the study, targeted, PEGylated nano-sized, co-drug (Fusidic acid (FA) and Levofloxacin (LEV)) encapsulated, <sup>68</sup>Ga-labeled, theranostic liposomes were formulated for osteomyelitis. Asp-DPPE and DOTA-Bn-DSPE were synthesized and confirmed by mass spectrometry, HPLC, FTIR-ATR, and XPS. The characterization of liposomes was carried out by assessing the particle size, zeta potential, encapsulation efficiency, obtaining CTEM images, drug release profiles, stability, and hydroxyapatite binding percentage. Additionally, in vitro antimicrobial activity was evaluated. Asp-Lipo/LEV/FA liposomes were developed nanosized (220,31 ± 2,40 nm) with sufficient encapsulation efficiencies (8,62 ± 1,27 for LEV and 31,20 ± 2,04 for FA). The highest <sup>68</sup>Ga-labeling yield was obtained at 60&#xa0;°C, pH 4.5, and 5 min for Asp-Lipo/LEV/FA. All liposomes were stable at 4&#xa0;°C for 30 days. Asp-Lipo/LEV/FA had significantly lower MIC values than Lipo/LEV/FA, and single-drug encapsulated liposomes for both <i>E. Coli</i> and <i>S. aureus</i> strains.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development, characterization, and in vitro evaluation of co-drug encapsulated, targeted theranostic liposomes for osteomyelitis

  • 期刊论文

  • 发表日期：

    2026年1月12日

查看全文
  • Asuman Tas,
  • Mine Silindir-Gunay,
  • Semih Calamak,
  • Seyma Nigiz,
  • Ahmet Cagkan Inkaya

摘要

Osteomyelitis is a bone infection marked by inflammation and swelling, with persistent challenges in diagnosis and treatment, especially in chronic and therapy-resistant pediatric cases. Within the scope of the study, targeted, PEGylated nano-sized, co-drug (Fusidic acid (FA) and Levofloxacin (LEV)) encapsulated, 68Ga-labeled, theranostic liposomes were formulated for osteomyelitis. Asp-DPPE and DOTA-Bn-DSPE were synthesized and confirmed by mass spectrometry, HPLC, FTIR-ATR, and XPS. The characterization of liposomes was carried out by assessing the particle size, zeta potential, encapsulation efficiency, obtaining CTEM images, drug release profiles, stability, and hydroxyapatite binding percentage. Additionally, in vitro antimicrobial activity was evaluated. Asp-Lipo/LEV/FA liposomes were developed nanosized (220,31 ± 2,40 nm) with sufficient encapsulation efficiencies (8,62 ± 1,27 for LEV and 31,20 ± 2,04 for FA). The highest 68Ga-labeling yield was obtained at 60 °C, pH 4.5, and 5 min for Asp-Lipo/LEV/FA. All liposomes were stable at 4 °C for 30 days. Asp-Lipo/LEV/FA had significantly lower MIC values than Lipo/LEV/FA, and single-drug encapsulated liposomes for both E. Coli and S. aureus strains.